| Cover | 12 Months Ended |
| Dec. 31, 2022 | |
| Document Information [Line Items] | |
| Document Type | DEF 14A |
| Amendment Flag | false |
| Entity Information [Line Items] | |
| Entity Registrant Name | KYMERA THERAPEUTICS, INC. |
| Entity Central Index Key | 0001815442 |
| Pay vs Performance Disclosure - USD ($) | 6 Months Ended | 10 Months Ended | 12 Months Ended | ||
| Dec. 31, 2021 | Oct. 22, 2021 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Pay vs Performance Disclosure [Table] | |||||
| Pay vs Performance [Table Text Block] | Pay versus Performance The following table reports the compensation for Dr. Mainolfi (our Principal Executive Officer, or PEO) and the average compensation of the other Named Executive Officers (Other NEOs) as reported in the Summary Compensation Table in our proxy statements for the past three fiscal years, as well as their “compensation actually paid” (CAP), as calculated pursuant to recently adopted SEC rules and certain performance measures required by the rules. The grant date fair values included in the Summary Compensation Table (SCT) have awards mation S-K. Pay Versus Performance Table Value of initial fixed $100 investment based on: Year Summary (1) Compensation (2) Average Summary (3) Average (4) Total Shareholder Peer Group (5) Net Loss (6) 2022 $ 6,926,645 ($ 24,973,497 ) $ 1,889,672 ($ 4,924,083 ) $ 75.05 $ 102.99 $ 154,808 2021 $ 11,573,374 $ 12,612,015 $ 3,329,398 $ 153,471 $ 190.89 $ 114.59 $ 100,217 2020 $ 3,678,001 $ 30,951,579 $ 1,812,465 $ 10,976,901 $ 186.41 $ 114.56 $ 45,593 (1) Dr. Mainolfi served as our PEO in each year shown. (2) The amounts reported represent the “compensation actually paid” to our PEO, computed in accordance with Item 402(v) of Regulation S-K, S-K, The PEO Summary Compensation Table to compensation actually paid (or CAP) reconciliation is summarized in the following table: Year Summary Summary Change in Change in Change in Fair value of PEO CAP 2022 $ 6,926,645 ($ 5,951,445 ) ($ 13,733,529 ) ($ 12,952,506 ) $ 737,338 — ($ 24,973,497 ) 2021 $ 11,573,374 ($ 10,621,667 ) $ 10,809,481 ($ 1,755,523 ) $ 2,606,351 — $ 12,612,015 2020 $ 3,678,001 ($ 2,845,382 ) $ 28,515,760 $ 728,664 $ 874,537 — $ 30,951,579 (3) The amounts reported represent the average of the amounts reported for the Other NEOs, in the “Total” column of the Summary Compensation Table in each applicable year. The names of each of the named executive officers included for purposes of calculating the average amounts were (i) for 2022, Bruce Jacobs, Dr. Jared Gollob, and Elaine Caughey, (ii) for 2021, Bruce Jacobs, Dr. Jared Gollob, Elaine Caughey (from June 21, 2021 until December 31, 2021), and Dr. Richard Chesworth (from January 1, 2021 until October 22, 2021), and (ii) for 2020, Bruce Jacobs, Dr. Jared Gollob, and Dr. Richard Chesworth. (4) The amounts reported represent the average “compensation actually paid” to the Other NEOs as a group, computed in accordance with Item 402(v) of Regulation S-K. S-K, The average Other NEO Summary Compensation Table to CAP reconciliation is summarized in the following table: Year Summary Summary Change in Change in Change in Fair value Other NEO CAP 2022 $ 1,889,672 ($ 1,420,223 ) ($ 2,443,461 ) ($ 3,218,544 ) $ 268,473 — ($ 4,924,083 ) 2021 $ 3,329,398 ($ 2,829,424 ) $ 2,589,240 ($ 713,569 ) $ 677,265 ($ 2,899,439 ) $ 153,471 2020 $ 1,812,465 ($ 1,967,228 ) $ 10,923,640 $ 65,080 $ 142,943 — $ 10,976,901 (5) Peer group TSR reflects the Nasdaq Biotechnology Index for all three fiscal years disclosed, which aligns with the peer group used in our Annual Report on 10-K (6) The dollar amounts reported represent the amount of net loss reflected in the Company’s audited financial statements for the applicable fiscal year. | ||||
| Named Executive Officers, Footnote [Text Block] | Bruce Jacobs, Dr. Jared Gollob, Elaine Caughey | Dr. Richard Chesworth | Bruce Jacobs, Dr. Jared Gollob, and Elaine Caughey | Bruce Jacobs, Dr. Jared Gollob, and Dr. Richard Chesworth. | |
| Peer Group Issuers, Footnote [Text Block] | Peer group TSR reflects the Nasdaq Biotechnology Index for all three fiscal years disclosed, which aligns with the peer group used in our Annual Report on 10-K | ||||
| PEO Total Compensation Amount | $ 6,926,645 | $ 11,573,374 | $ 3,678,001 | ||
| PEO Actually Paid Compensation Amount | $ (24,973,497) | 12,612,015 | 30,951,579 | ||
| Adjustment To PEO Compensation, Footnote [Text Block] | The PEO Summary Compensation Table to compensation actually paid (or CAP) reconciliation is summarized in the following table: Year Summary Summary Change in Change in Change in Fair value of PEO CAP 2022 $ 6,926,645 ($ 5,951,445 ) ($ 13,733,529 ) ($ 12,952,506 ) $ 737,338 — ($ 24,973,497 ) 2021 $ 11,573,374 ($ 10,621,667 ) $ 10,809,481 ($ 1,755,523 ) $ 2,606,351 — $ 12,612,015 2020 $ 3,678,001 ($ 2,845,382 ) $ 28,515,760 $ 728,664 $ 874,537 — $ 30,951,579 | ||||
| Non-PEO NEO Average Total Compensation Amount | $ 1,889,672 | 3,329,398 | 1,812,465 | ||
| Non-PEO NEO Average Compensation Actually Paid Amount | $ (4,924,083) | 153,471 | 10,976,901 | ||
| Adjustment to Non-PEO NEO Compensation Footnote [Text Block] | The average Other NEO Summary Compensation Table to CAP reconciliation is summarized in the following table: Year Summary Summary Change in Change in Change in Fair value Other NEO CAP 2022 $ 1,889,672 ($ 1,420,223 ) ($ 2,443,461 ) ($ 3,218,544 ) $ 268,473 — ($ 4,924,083 ) 2021 $ 3,329,398 ($ 2,829,424 ) $ 2,589,240 ($ 713,569 ) $ 677,265 ($ 2,899,439 ) $ 153,471 2020 $ 1,812,465 ($ 1,967,228 ) $ 10,923,640 $ 65,080 $ 142,943 — $ 10,976,901 | ||||
| Compensation Actually Paid vs. Total Shareholder Return [Text Block] | PEO and Other NEO Compensation Actually Paid and Company Total Shareholder Return (“TSR”) Equity awards are the largest component of our executive compensation program, representing no less than 69% of the target total compensation for each of our executives. Therefore, TSR has a significant impact on our CAP, particularly for executives who have been with us for several years and who have multiple years of outstanding equity awards. The impact is more pronounced for our CEO/PEO, given the 100% weighting of stock options as part of his compensation versus the Other NEOs who receive a blend of stock options and restricted stock units and the larger size of his annual equity awards. Due to the significant weighting of equity in our compensation programs, the decline in our stock price between the end of 2021 and 2022 has resulted in negative CAP for our PEO and Other NEOs. TSR for our peer group is based on the Nasdaq Biotechnology Index (XNBI), which reflects the Company’s industry sector and is also the peer group used in our Annual Report on Form 10-K. KT-474 | ||||
| Compensation Actually Paid vs. Net Income [Text Block] | Compensation Actually Paid and Net Loss Because we are not a commercial-stage company, we did not have any revenue during the periods presented, other than the recognition of non-cash | ||||
| Compensation Actually Paid vs. Company Selected Measure [Text Block] | Description of the Relationship Between Compensation Actually Paid and Selected Performance Metrics As described above in the section titled “Compensation Discussion and Analysis on” on page 24, our compensation program is designed to attract and retain high-performing talent in our industry, motivate our executive officers to create long-term, enhanced shareholder value, and provide a fair reward for executive effort and stimulate professional and personal growth. The Company uses several performance measures to align executive compensation with Company performance, not all of which are presented in the Pay versus Performance table above. Moreover, the Company calculates compensation to the PEO and other NEOs on a basis different than the amount reported in the Summary Compensation Table and, compensation actually paid, as calculated in accordance with Item 402(v) of Regulation S-K, S-K, | ||||
| Total Shareholder Return Vs Peer Group [Text Block] | TSR for our peer group is based on the Nasdaq Biotechnology Index (XNBI), which reflects the Company’s industry sector and is also the peer group used in our Annual Report on Form 10-K. KT-474 | ||||
| Total Shareholder Return Amount | $ 75.05 | 190.89 | 186.41 | ||
| Peer Group Total Shareholder Return Amount | 102.99 | 114.59 | 114.56 | ||
| Net Income (Loss) | $ 154,808,000 | 100,217,000 | 45,593,000 | ||
| PEO Name | Dr. Mainolfi | ||||
| PEO [Member] | Summary Compensation Table Total Equity [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | $ (5,951,445) | (10,621,667) | (2,845,382) | ||
| PEO [Member] | Change in Value of Prior Years Awards Unvested at FYE [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | (13,733,529) | 10,809,481 | 28,515,760 | ||
| PEO [Member] | Change In Value Of Prior Years Awards That Vested In FY [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | (12,952,506) | (1,755,523) | 728,664 | ||
| PEO [Member] | Change In Value Of Equity Awards Granted And Vested In FY [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | 737,338 | 2,606,351 | 874,537 | ||
| PEO [Member] | Fair Value Of Awards Forfeited In FY [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | 0 | 0 | 0 | ||
| Non-PEO NEO [Member] | Summary Compensation Table Total Equity [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | (1,420,223) | (2,829,424) | (1,967,228) | ||
| Non-PEO NEO [Member] | Change in Value of Prior Years Awards Unvested at FYE [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | (2,443,461) | 2,589,240 | 10,923,640 | ||
| Non-PEO NEO [Member] | Change In Value Of Prior Years Awards That Vested In FY [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | (3,218,544) | (713,569) | 65,080 | ||
| Non-PEO NEO [Member] | Change In Value Of Equity Awards Granted And Vested In FY [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | 268,473 | 677,265 | 142,943 | ||
| Non-PEO NEO [Member] | Fair Value Of Awards Forfeited In FY [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | $ 0 | $ (2,899,439) | $ 0 | ||
